- €33.15m
- €31.65m
- €15.73m
Brief: Biohit Board Elects Kari Syrjänen As Chairman
Brief: Biohit Reports Revenue Of EUR 8.3 Mln For Jul-Dec 2025
Brief: Biohit, Restalyst Partner To Improve Non-Invasive Early Gastric Cancer Detection
Brief: Biohit Keeps 2024 Outlook Unchanged
Brief: Biohit Says Had Strong First Half Of 2023
Brief: Biohit H1 Revenue at EUR 6.5 Million
Brief: Biohit Posts FY Net Loss of EUR 0.6 Million
Brief: Biohit Gastropanel Enters Global Market By Cooperation With Randox
Brief: Biohit Appoints Jussi Sorvo As CFO
Brief: Biohit's CEO Resigns
Brief: Biohit H1 Operative EBITDA Turns To Profit Of EUR 1.7 MLN
Brief: Biohit Upgrades 2022 Outlook, Says Prelim H1 EBIT Up At EUR 1.3 Mln
Brief: Biohit H2 Operative EBITDA Swings To Profit Of EUR 0.7 Mln
Brief: Biohit H1 EBITDA Loss Narrows To EUR 0.2 Mln
Brief: Biohit: CE Marked Gastropanel Quick Test On The Market
Brief: Päivi Siltala New CEO Of Biohit Oyj
Brief: Biohit Oyj Says President And CEO Semi Korpela To Leave The Company
Brief: Biohit's CEO Is On Sick Leave
Brief: Biohit July-Dec Operative EBITDA Swings To Loss Of EUR 0.2 Million